All Articles

A new AI-designed vaccine, TG4050, has prevented relapse in all head and neck cancer patients in a key trial, signaling a breakthrough in personalized medicine.

A major pharma giant is betting on artificial intelligence to accelerate cancer drug discovery, a move that could reshape the future of oncology treatment.

At CES 2026, an awards ceremony marks two decades of upheaval, chronicling China's rise from follower to leader in the global electronics industry.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

Making its CES debut, Chinese supplier InfiMotion unveiled next-gen electric drives that promise more power and efficiency in a lighter, integrated package.

AS Tallinna Sadam reports robust 2025 results, with a major jump in liquid bulk cargo and a strong rebound in cruise tourism signaling regional recovery.

Swiss lab automation giant Tecan shows signs of a turnaround with robust H2 2025 orders, betting on AI to navigate a recovering life sciences market.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

A new report reveals shifting consumer demands for THCA flower, as the booming market grapples with quality standards and a complex regulatory future.

FieldBee Vision's gold medal win at LAMMA 2026 signals a new era of accessible, AI-driven precision agriculture for farms of all sizes.

A new partnership aims to empower one of Asia's most vulnerable workforces with crucial financial skills, tackling debt, scams, and future planning.

Chery Australia's new campaign does more than sell cars; it aims to drive tourism to regional Australia and redefine the classic family road trip.

The smartphone giant joins the VVC Advance patent pool, a key move poised to speed up the adoption of next-gen video codecs for consumers worldwide.

Ventyx Biosciences is under investigation for misleading investors after a trial delay caused a 15% stock drop, even as a pharma giant moves to acquire it.

Dr. Jill Tarter, the real-life inspiration for 'Contact,' wins the Green Sands Prize, validating her decades-long quest to legitimize the search for E.T.

A key regulatory shift enables US-based Monnit to partner with Widetec, aiming to solve Japan's labor and infrastructure challenges with IoT solutions.

Boston's Moody Aldrich Partners commits $600M to London's SCIO Capital, a major validation of specialized asset-backed lending in Europe's booming market.

The energy giant raises its dividend for the 54th straight year, cementing its status as a top 'dividend aristocrat' for income-focused investors.

The P&C insurance tech leader leverages its strong cash position for a massive buyback, signaling confidence amid its successful cloud transformation.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.